Clinicopathological characteristics and prognostic impact of colorectal cancers with NRAS mutations

Oncology Reports

Volumn 32, Issue 1, 2014, Pages 50-56

  Ogura, Toshiro ^a,b   Kakuta, Miho ^a   Yatsuoka, Toshimasa ^a   Nishimura, Yoji ^a   Sakamoto, Hirohiko ^a   Yamaguchi, Kensei ^a   Tanabe, Minoru ^b   Tanaka, Yoichi ^a   Akagi, Kiwamu ^a  

^a SAITAMA CANCER CENTER   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

BRAF; Colorectal cancer; KRAS; Microsatellite instability; NRAS

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; GUANOSINE TRIPHOSPHATASE; KRAS PROTEIN, HUMAN; MEMBRANE PROTEIN; NRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER LOCALIZATION; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; COLORECTAL CANCER; CONTROLLED STUDY; EXON; FEMALE; GENE IDENTIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; COLORECTAL NEOPLASMS; GENETICS; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; SURVIVAL;

AGED; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GTP PHOSPHOHYDROLASES; HUMANS; MALE; MEMBRANE PROTEINS; MICROSATELLITE INSTABILITY; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; SURVIVAL ANALYSIS;

EID: 84903183816     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3165     Document Type: Article

References (39)

1. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006. (Pubitemid 44497237)
2. Mendelsohn J and Baselga J: Epidermal growth factor receptor targeting in cancer. Semin Oncol 33: 369-385, 2006. (Pubitemid 44142736)
3. Fang JY and Richardson BC: The MAPK signalling pathways and colorectal cancer. Lancet Oncol 6: 322-327, 2005. (Pubitemid 40590269)
4. Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308, 2007. (Pubitemid 46480970)
5. Ginesta MM, Mora J, Mayor R, et al: Genetic and epigenetic markers in the evaluation of pancreatic masses. J Clin Pathol 66: 192-197, 2013.
6. Mascaux C, Iannino N, Martin B, et al: The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 92: 131-139, 2005. (Pubitemid 40188446)
7. Kohlmann A, Grossmann V, Klein HU, et al: Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol 28: 3858-3865, 2010.
8. Uhara H, Ashida A, Koga H, et al: NRAS mutations in primary and metastatic melanomas of Japanese patients. Int J Clin Oncol: June 6, 2013 (Epub ahead of print).
9. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762, 2010.
10. Vaughn CP, Zobell SD, Furtado LV, Baker CL and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. Genes Chromosomes Cancer 50: 307-312, 2011.
11. Loupakis F, Ruzzo A, Cremolini C, et al: KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721, 2009.
12. Irahara N, Baba Y, Nosho K, et al: NRAS mutations are rare in colorectal cancer. Diagn Mol Pathol 19: 157-163, 2010.
13. Seymour MT, Brown SR, Middleton G, et al: Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol 14: 749-759, 2013.
14. Smith CG, Fisher D, Claes B, et al: Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin Cancer Res 19: 4104-4113, 2013.
15. Farina-Sarasqueta A, van Lijnschoten G, Moerland E, et al: The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients. Ann Oncol 21: 2396-2402, 2010.
16. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417, 2009.
17. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671, 2009.
18. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765, 2008.
19. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28: 4697-4705, 2010.
20. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26: 1626-1634, 2008.
21. Douillard JY, Oliner KS, Siena S, et al: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369: 1023-1034, 2013.
22. Samowitz WS, Sweeney C, Herrick J, et al: Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65: 6063-6069, 2005.
23. Roth AD, Tejpar S, Delorenzi M, et al: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474, 2010.
24. Imamura Y, Morikawa T, Liao X, et al: Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 18: 4753-4763, 2012.
25. Lochhead P, Kuchiba A, Imamura Y, et al: Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J Natl Cancer Inst 105: 1151-1156, 2013.
26. Gavin PG, Colangelo LH, Fumagalli D, et al: Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value. Clin Cancer Res 18: 6531-6541, 2012.
27. Ogino S, Shima K, Meyerhardt JA, et al: Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin Cancer Res 18: 890-900, 2012.
28. Akagi K, Uchibori R, Yamaguchi K, Kurosawa K, Tanaka Y and Kozu T: Characterization of a novel oncogenic Kras mutation in colon cancer. Biochem Biophys Res Commun 352: 728-732, 2007. (Pubitemid 44880315)
29. Asaka S, Arai Y, Nishimura Y, et al: Microsatellite instability-low colorectal cancer acquires a KRAS mutation during the progression from Dukes' A to Dukes' B. Carcinogenesis 30: 494-499, 2009.
30. Ishikubo T, Nishimura Y, Yamaguchi K, et al: The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer Lett 216: 55-62, 2004. (Pubitemid 39410496)
31. Andreyev HJ, Norman AR, Cunningham D, Oates JR and Clarke PA: Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. J Natl Cancer Inst 90: 675-684, 1998. (Pubitemid 28222141)
32. Yokota T, Ura T, Shibata N, et al: BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104: 856-862, 2011.
33. Oh JR, Kim DW, Lee HS, et al: Microsatellite instability testing in Korean patients with colorectal cancer. Fam Cancer 11: 459-466, 2012.
34. Yamauchi M, Morikawa T, Kuchiba A, et al: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 61: 847-854, 2012.
35. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937, 2009.
36. Phipps AI, Buchanan DD, Makar KW, et al: KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer 108: 1757-1764, 2013.
37. Tol J, Koopman M, Cats A, et al: Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 360: 563-572, 2009.
38. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol 22: 1535-1546, 2011.
39. Fornaro L, Lonardi S, Masi G, et al: FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol 24: 2062-2067, 2013.